2016 American Transplant Congress Archives - Page 178 of 180

T-Bet Regulates nTreg Stability and Suppression in an Islet Allograft Model.

Y. Xiong, S. Ahmad, D. Iwami, C. Brinkman, J. Bromberg.
Tacrolimus (Tac), Rather Than Cyclosporine (CsA), Interacts with Insulin Resistance (IR) to Alter Key Transcription Factors for β-Cell Identity & Function without Altering NFAT Localization.

J. Triñanes,¹ A. Rodriguez,² E. de Koning,¹ J. de Fijter,¹ F. Carlotti,¹ A. Torres,² A. de Vries,¹ E. Porrini.²
Tacrolimus as a Tool for Intracellular Assessment of von Willebrand Factor Production by Activated Human Glomerular Endothelial Cells.

S. Béland, P. Vallin, O. Désy, S. De Serres.
Tacrolimus Dosing, Trough Concentrations and Dose Adjustments Compared Between Two Generic Formulations in Adult Kidney Transplant Recipients.

D. Taber, V. Phan, A. Wilton, N. Pilch, H. Meadows, J. Fleming, C. Mardis, A. Mardis, C. Bratton, K. Chavin, J. McGillicuddy, S. Nadig, P. Baliga.
Tacrolimus Levels in Patients Treated with Direct Acting Antivirals Post-Transplant.

J. Wiegel, T. Egbuka.
Tacrolimus Precision Medicine: Antibiotics Increase Intra-Patient Variability in Tacrolimus Trough Concentrations in Kidney Transplant Recipients.

Y. Zheng, J. Lee, A. Masand, D. Dadhania, M. Thangamani, M. Suthanthiran.
Tailored Rabbit Anti-Thymocyte Globulin Induction (rATG) Dosing for Kidney Transplantation.

N. Singh,^1,2 A. Rossi,¹ M. Savic,¹ R. Rubocki,¹ M. Parker,¹ J. Vella.¹
Targeting IFN-g-Expressing TIM-4⁺B Effector (Beff) Cells as a Novel Strategy to Prevent Allograft Rejection.

Q. Ding,¹ K. Mohib,¹ S. Xiao,² V. Kuchroo,² D. Rothstein.¹
Targeting the Constitutively Active PI3K/Akt/mTOR Signaling Pathway in Epstein-Barr Virus B Cell Lymphomas.

A. Sang, G. Ivison, C. Esquivel, S. Krams, O. Martinez.
Technique of “Loop V-Plasty” for Combined Reconstruction of the Middle Hepatic Vein and Multiple Inferior Right Hepatic Veins Using Single Polytetrafluoroethylene Graft in a Right Lobe Living Donor Liver Transplantation.

T.-H. Chen, L. Noriega, A. Thorat, P.-C. Li, H.-R. Yang, S.-C. Hsu, L. Jeng, M.-L. Li.
Telemedicine to Reduce Readmissions Post Liver Transplant: Compliance and Feasibility Results.

T. Kaiser,¹ P. Kimmel,² S. Osborn,² S. Diersing,² B. Boswell,² J. Huff,² J. Garrett,¹ N. Anwar,¹ S. Shah.¹
Text Messaging Facilitates Follow-Up Communication with Live Donors.

J. Moore, A. Massie, J. Berger, J. Montgomery, S. Dorry.
TGFb in Regulatory B Cells-Dependent Tolerance.

H. Deirawan, L. Kojima, L. Washburn, J. Markmann, J. Kim.
Th17 Development Is Critical for Airway Epithelial Injury After Transplantation.

J. Xu, Y. Zhang, L. Wang, X. Li, R. Chen, R. Zhang, Y. Ding.
The “PHS Increased Risk” Label Is Associated with Non-Utilization of Hundreds of Organs Per Year.

M. Volk,¹ A. Wilk,² C. Wolfe,³ D. Kaul.⁴
The 20S Proteasome, Active within Exosome-Like Vesicles Released by Apoptotic Cells Accelerates Rejection.

M. Dieudé,^1,4,5 C. Bell,^2,5 J. Turgeon,^1,5 D. Beillevaire,^1,4,5 S. Qi,^1,5 E. Boilard,^3,5 P. Thibault,^2,5 M.-J. Hébert.^1,4,5
The Apoptosis of the Tracheal Epithelia Increase the Recipient's MSCs Derived Myofibroblasts in Allografts to Exacerbate Obliterative Bronchiolitis After Tracheal Transplantation in Mice.

C. Wang,¹ T. Xia,¹ X. Zhang,² K. Jiang,¹ J. Wang,¹ J. Nie.¹
The Association of Life Expectancy by Resident Zip Code and Kidney Transplant Outcomes – What Is True Baseline Risk?

L. Buccini, D. Goldfarb, E. Poggio, S. Flechner, J. Schold.
The Bacterial Enzyme IdeS, Inhibits HLA Antibody-Mediated NK Cell Activation and Cell Cytotoxicity (ADCC) In Vitro.

S. Ge, M. Chu, J. Choi, S. Jordan, M. Toyoda.
The BEST Trial: A Prospective Randomized Trial of Belatacept-Based, CNI- and Corticosteroid-Free Immunosuppression.

E. Woodle,¹ D. Kaufman,² A. Shields,¹ J. Leone,³ A. Matas,⁴ A. Wiseman,⁵ P. Thielke,⁶ R. Alloway.¹
The Burden and Outcomes of Fractures in Kidney Transplant Recipients.

N. Atagu, T. Nguyen, N. Phan, O. Famure, Y. Li, J. Kim.
The Clinical Differences Between First and Second Kidney Transplant in IgA Nephropathy: A Multicenter Retrospective Study.

C. Baek,¹ J. Lee,² J. Park,³ H. Kim,¹ Y. Kim,² W. Huh,³ J. Yang,⁴ D. Han,⁵ S.-K. Park.¹
The Coefficient of Variability of Tacrolimus Levels Can Predict Antibody-Mediated Rejection After Renal Transplantation.

P. Ruiz-Esteban,¹ M. Gonzalez-Molina,¹ A. Caballero,² E. Palma,¹ D. Burgos,¹ M. Cabello,¹ J. Alonso-Titos,¹ A. Duarte,¹ D. Hernandez.¹
The Combined Effect of Acute Rejection and De Novo Donor-Specific Antibodies on Kidney Allograft Survival.

S. Davis, J. Gralla, A. Wiseman, J. Cooper.
The Correlation of Hepatic and Systemic Hemodynamics During Liver Transplantation: Quantification of Hepatic Resistance as an Actual Value.

A.-C. Feng, T.-W. Chen, H.-L. Fan, J.-C. Yu, C.-B. Hsieh.
The Distance Between Us: The Landscape of Recipient-Specific Loss-of-Function in Solid Organ Transplantation and Association with Rejection-Free Graft Survival.

B. Cole,^1,2,5 J. van Setten,^3,5 B. Keating.^1,4,5
The Early Outcomes of Bortezomib Therapy in Patients with Late Antibody Mediated Rejection in Renal Transplantation.

J. Choi, J. Jung, S. Shin, Y. Kim, D. Han.
The Effect of Body Mass Index on Lung Transplant Outcomes.

M. Kashem,¹ A. Shiose,¹ J. Abraham,¹ N. Dean,¹ S. Breves,¹ F. Cordova,² N. Patel,² T. Yoshizumi,¹ G. Criner,² Y. Toyoda.¹
The Effect of Bortezomib on DSA Reduction During the Treatment of AMR in Pediatric Kidney Transplant Patients.

O. Moussa, S. Self, K. Twombley.
The Effect of Donor Age on Acute Rejection Age – The Clinical Impact of Donor Immuno-Senescence in the Modern Immunosuppressive Era.

U. Khalid, P. Donato, L. Szabo, R. Chavez, E. Ablorsu, A. Asderakis.
The Effect of Donor-Recipient Relationship on the Immunologic Outcome in Living Kidney Transplantation.

D. Khadzhynov, F. Halleck, L. Lehner, M. Duerr, J. Waiser, K. Budde, O. Staeck.
The Effect of DRI and KDPI on Outcomes of High MELD Patients Undergoing Simultaneous Liver Kidney Transplant.

E. Chan,¹ M. Hertl,¹ J. Perkins.²
The Effect of Everolimus and Tacrolimus Exposure Levels on Renal Histology Parameters 6 Months Post-Transplantation.

S. Yilmaz,¹ D. Shaffer,² Y. Qazi,³ K. McCague,⁴ D. Patel,⁴ V. Peddi,⁵ F. Vincenti.⁶
The Effect of Families on Organ Donation Among Native Americans.

T. Bongiovanni,^1,3 J. Rawlings,² J. Trompeta.¹
The Effect of Immunosuppression Regimen on Iga Nephropathy Recurrence Post Kidney Transplantation.

K. Koutroutsos,¹ A. Kousios,¹ L. Leighton,¹ R. Charif,¹ D. Goodall,¹ T. Cook,² J. Galliford,¹ D. Taube,¹ M. Loucaidou.¹
The Effect of Maternal Graft in Early Acute Cellular Rejection After Pediatric Living Donor Liver Transplantation.

Y. Noguchi,¹ T. Ueno,¹ K. Bessho,² Y. Takama,¹ H. Yamanaka,¹ N. Tanaka,¹ Y. Tazuke,¹ H. Okuyama.¹
The Effect of Rituximab on Hepatitis B Reactivation in Kidney Transplant Recipients with Resolved Hepatitis B.

J. Lee,¹ J. Park,² J. Lee,¹ S. Song,¹ J. Lee,¹ S.-K. Kwon,¹ K. Huh,¹ B. Kim,³ M. Kim,¹ S. Kim,¹ S. Ahn,² Y. Kim.¹
The Effect of Spironolactone on Calcineurininhibitor Induced Nephrotoxicity.

L. Mortensen,¹ H. Thiesson,¹ C. Bistrup,¹ F. Nielsen,³ U. Halekoh,² B. Jensen,³ N. Marcussen.⁴
The Effect of the Use of a TNF-Alpha Inhibitor in Hypothermic Machine Perfusion on Kidney Function After Transplantation.

P. Diuwe,¹ P. Domagala,¹ R. Kieszek,¹ M. Wszola,¹ M. Serwanska-Swietek,¹ L. Paczek,² M. Durlik,³ A. Chmura,¹ A. Kwiatkowski.¹
The Effect of Tocilizmab Treatment (TCZ-Rx) on IgG Subclasses in HLA-sensitized (HS) Kidney Transplant Patients Treated with TCZ.

B.-H. Shin, S. Ge, J. Choi, J. Kahwaji, A. Vo, A. Petrosyan, S. Jordan, M. Toyoda.
The Effect of Tocilizmab Treatment (TCZ-Rx) on Total IgG and Anti-CMV-IgG Levels in HLA-Sensitized (HS) Kidney Transplant Patients.

B.-H. Shin, S. Ge, J. Choi, J. Kahwaji, A. Vo, A. Petrosyan, S. Jordan, M. Toyoda.
The Effects of Brain Death and Ischemia on Tolerance Induction Are Organ-Specific.

S. Michel,^1,2 M. Madariaga,¹ G. LaMuraglia II,¹ R. Colvin,³ E. Farkash,³ J. Allan,^1,4 D. Sachs,¹ K. Yamada,¹ J. Madsen.^1,5
The Environmental Impact of Dialysis vs Transplantation.

M. Grafals,¹ R. Sanchez.²
The Epidemiology of Clostridium difficile Infection in a National Kidney Transplant Center.

C. Kennedy,¹ C. Waldron,¹ M. Scally,² K. Burns,² C. Magee,¹ F. Fitzpatrick.²
The Finances of Broader Sharing of Livers Following Share 35.

A. Harper,¹ E. Edwards,¹ R. Gilroy,² W. Chapman,³ D. Mulligan,⁴ G. Klintmalm.⁵
The Fine-Tuning of CXCL8 Protects Kidney Against Ischemia-Reperfusion Injury in Mice Lacking MicroRNA-146a.

L. Amrouche,^1,2 G. Desbuissons,¹ M. Rabant,^1,2 C. Legendre,^1,2 F. Terzi,² D. Anglicheau.^1,2
The First 48 Months of an Australian Renal and Liver Organ Transplant Dermatology Database.

L. Ge,^1,2 P. Lowe.^1,2
The First Impressions: A Study in Pre and Post-Implantation Renal Grafts for Early Detection Markers of Delayed Graft Function and Recovery.

S. Bontha,¹ L. Suh,¹ P. Dormish,¹ R. Gehrau,¹ E. Rhone,¹ L. Gallon,³ A. King,² C. Dumur,² D. Maluf,¹ V. Mas.¹
The Function of CD8⁺TCR^– Facilitating Cells and Regulatory T Cells Is Impaired in Flt3-Ligand Knockout Mice.

Y. Huang, H. Xu, T. Miller, Y. Wen, S. Ildstad.
The Heterogenous Genomic Landscape of Unresectable Hepatoblastoma Requiring Liver Transplantation: Prognostic Implications.

M. Ningappa, B. Higgs, S. Ranganathan, C. Ashokkumar, R. Sindhi.
The IFN-Gamma-Inducible Protein (IP-10/CXCL10) Is a Promising Target to Improve Endocrine Function Following Islet Transplantation.

G. Yoshimatsu,¹ M. Kanak,² P. Balaji S,¹ C. Chang,³ C. Darden,³ M. Takita,¹ M. Lawrence,¹ B. Naziruddin.⁴
The Immunologic Profile of Brain Death in Humans: A Whole-Body Analysis.

D. Carpenter,^1,2 N. Matsuoka,¹ J. Thome,^1,3 T. Granot,^1,3 C. Gordon,^1,3 B. Kumar,^1,3 T. Senda,^1,3 M. Miron,^1,3 J. Weiner,² A. Griesemer,^1,2 D. Farber.^1,2,3
The Impact of a Novel Dual Adenosine Triphosphate-Competitive mTOR Inhibitor (TORKinib) on Alloimmunity and Transplant Survival.

D. Fantus,¹ Y. Ono,¹ S. Yokota,¹ C. Komatsu,¹ H. Turnquist,^1,2 A. Thomson.^1,2
The Impact of Allograft Rejection on DNA Methylation After Kidney Transplantation.

K. Boer, E. de Wit, D. Hesselink, L. Hofland, M. Betjes, C. Baan.
The Impact of Body Mass Index > 35 on Kidney Transplant Outcomes: A Systematic Review.

D. Walczak, E. Benedetti.
The Impact of CMS Policy on Delisting of "Too Sick" Liver Transplant Candidates.

N. Dolgin, B. Movahedi, P. Martins, A. Bozorgzadeh.
The Impact of Complement Binding Donor Specific Antibodies in the First Year After Heart Transplantation.

J. Patel, M. Kittleson, D. Chang, T. Aintablian, A. Velleca, D. Ramzy, L. Czer, J. Kobashigawa.
The Impact of Different Immunosuppressive Protocols on Early and Long Term Outcomes After Kidney and Pancreas Transplantation.

A. Rajab, R. Pelletier, A. El-Hinnawi, E. Elkhammas, G. Bumgardner, M. Henry.
The Impact of Donor Origin on Survival after Orthotopic Heart Transplantation.

O. Kiamanesh, A. Khosla, C. Imai, E. Johansson, S. Virani, M. Davis, A. Cheung, J. Bashir, B. Munt, A. Ignaszewski, A. Kaan, M. Toma.
The Impact of Donor Procurement Characteristics in Contemporary Live Donor Pediatric Renal Transplantation Outcomes: An Analysis of 282 Cases.

Z. Ahmed,¹ R. Uwechue,¹ P. Chandak,¹ J. Stojanovic,² N. Kessaris,¹ N. Mamode.¹
The Impact of Early Acute Rejection and Delayed Graft Function on Graft Outcomes at Six Months in Adult Deceased Donor Kidney Recipients.

D. Keith, G. Vranic, A. Nishio Lucar.
The Impact of Etiology of Liver Disease and Indication for Transplantation on Access to the Liver Transplant Waiting List in the United States.

D. Goldberg,^1,2 B. French,² C. Newcomb,² Q. Liu,² J. Lewis,^1,2 S. Halpern.^1,2
The Impact of Gender Discordance on Graft Survival Among Liver Transplant Recipients.

J. Moore, X. Luo, A. Massie, T. Purnell, D. Mogul, D. Segev.
The Impact of Graft Thin Upper Pole Arterial Branch Ligation on Adult Living Donor Kidney Transplantation.

T. Hiramitsu, M. Okada, T. Yamamoto, M. Tsujita, N. Goto, S. Narumi, Y. Watarai.
The Impact of Kidney Donor Profile Index (KDPI) on Rates of Delayed Graft Function (DGF).

T. Zens, G. Leverson, R. Redfield, P. Chlebeck, L. Zitur, D. Kaufman, L. Fernandez.
The Impact of Microvascular Inflammation (MVI) in Kidney Transplant Biopsies (KTxBx) Is Independent of Time Post-Transplant.

R. Gaston,¹ J. Grande,² R. Leduc,³ The DeKAF Study Group.
The Impact of Non-Adherence on Disparities in African-American Kidney Transplant Recipients.

D. Taber, A. Chokkalingam, A. Posadas, R. Browning, N. Salazar, M. Kamel, R. Pullalarevu, B. Kadri, T. Srinivas, K. Chavin, P. Baliga.
The Impact of One Year Individual or Dual Organ Rejection in Simultaneous Pancreas-Kidney Transplant on Kidney Graft Survival – A UNOS Registry Analysis 2000-2013.

I. Moinuddin,¹ T. Taber,¹ M. Yaqub,¹ O. Adebiyi,¹ M. Mujtaba,¹ J. Chen,² M. Goble,² D. Mishler,¹ J. Fridell,² A. Sharfuddin.¹
The Impact of Pre-Donation eGFR on Recipient Outcomes, as a Function of Donor Age.

J. Gill,¹ J. Dong,² O. Djurdjev,² J. Lesage,¹ C. Rose,¹ J. Gill.¹
The Impact of Pre-Transplant Infections on Post-Liver Transplant Outcomes.

S. Ngo, J. Levitsky, M. Ison.
The Impact of Readmission following Kidney Transplantation: Is Readmission Becoming More Risky?

E. King, L. Kucirka, M. McAdams-DeMarco, A. Massie, D. Segev.
The Impact of Ritonavir-Boosted Protease Inhibitors and Non-Depleting Antibody Induction on Outcomes in HIV-Infected Kidney Transplant Recipients.

B. Rollins, S. Lerner, M. Rana, S. Huprikar, L. Miko, V. Nair, S. Florman, R. Shapiro.
The Impact of Sequential Gene Modifications on Cardiac Xenograft Survival.

K. Horvath,¹ A. Singh,¹ J. Chan,¹ M. Thomas,² B. Lewis,² D. Ayares,³ P. Corcoran,¹ M. Mohiuddin.¹
The Impact of Share 35 on Liver Allocation and Utilization: One DSA's Experience.

J. Orlowski, C. Muse, J. Whaley, R. Squires.
The Impact of Thromboelastography on Resuscitation in Pediatric Liver Transplantation.

K. Gonzalez,¹ K. Curiel,¹ B. Dalton,¹ V. Fioravanti,¹ W. Andrews,¹ B. Wicklund,² R. Hendrickson.¹
The Impact of Total Ischaemic Time, Donor Age and the Pathway of Donor Death on Graft Outcomes After Deceased Donor Kidney Transplantation.

G. Wong,¹ A. Teixeira-Pinto,¹ C. Jeremy,¹ C. Jonathan,¹ M. Stephen,² L. Wai.³
The Impact of Treating Borderline Cellular Rejections.

R. Mustafa,¹ Y. Al Azzi,¹ J. Crew,¹ G. Dube,¹ H. Morris,¹ M. Chiles,¹ J. Chang,¹ H. Fernandez,¹ D. Cohen,¹ I. Batal,² E. Campenot,² S. Mohan.¹
The Importance of KDPI in Simultaneous Liver and Kidney Transplant.

E. Chan,¹ M. Hertl,¹ J. Perkins.²
The Incidence of Symptomatic Pericardial Effusion with Long-Term Sirolimus Therapy.

N. Chandolias,¹ S. Wang,¹ A. Hahn,¹ R. Lyubarova,² R. Lopez-Soler,¹ D. Conti.¹
The Incidence, Risk Factors and Clinical Course of De Novo Hepatitis B Infection in Pediatric Living Donor Liver Transplantation.

Z. Baris, F. Ozcay, G. Moray, M. Haberal.
The Increase of Serum MiR-142-3p Level in Acute Cardiac Rejection as a Reflection of Exosome-Mediated Genetic Exchange Between T Cells and Endothelial Cells.

I. Dewi,¹ Z. Hollander,² B. McManus,² O. Gidlöf,¹ J. Öhman.¹
The Influence of Rising Lab MELD on Vascular Invasion in HCC.

K. Halazun, E. Przybyszewski, E. Verna, B. Samstein, A. Fox, R. Brown, J. Emond.
The Influence of Static versus Machine Dynamic Perfusion Kidney Graft Preservation on Delayed Graft Function Incidence: A Prospective, Randomized Study.

H. Marinho Neto, V. Aires, J. Offerni, W. Luconi, P. Luconi, S. Braga, I. Noronha, R. Barsante, J. Moreira, A. Savina, L. Kuschnaroff, F. Lemos, A. Cuvello, P. Chocair, L. Moura, A. Silva Filho, I. Charpiot, M. Abbud Filho, M. Cunha, P. Malafonte, D. Demetrio, L. Miorin, A. Duboc Filho, A. Claudini, W. Aguiar, H. Tedesco, J. Medina Pestana.
The Intrarenal Resistive Index Measured After Transplantation Is Determined by the Upstream Vascular System of the Recipient.

L. Heylen,¹ M. Naesens,¹ B. Sprangers,¹ S. Heye,² P. Verhamme,³ I. Jochmans,⁴ D. Monbaliu,⁴ J. Pirenne,⁴ D. Kuypers,¹ K. Claes.¹
The Largest Single Center Experience with Total Artificial Heart Implantation: Characterization of Outcome.

F. Arabia, M. Kittleson, L. Czer, D. Chang, T. Aintablian, E. Passano, G. Rodriguez, C. Runyon, J. Kobashigawa, J. Moriguchi.
The Live Donor Champion Program: A Novel Approach to Identying Live Kideny Donors.

E. King, M. Bowring, K. Kumar, J. Garonzik Wang, D. Segev.
The Long and Short of Old and Cold on Renal Allograft Outcomes.

A. Naik,¹ D. Luan,¹ K. Lentine,² P. Rao,¹ A. Sakhuja,¹ Y. Huang,¹ M. Samaniego,¹ S. Norman,¹ A. Ojo,¹ D. Cibrik.¹
The Medication Level Variability Index (MLVI), a Behavioral Biomarker, Predicts Late Allograft Rejection in Pediatric Liver Transplant Recipients – A Prospective Multisite Study.

E. Shemesh,¹ J. Bucuvalas,² R. Anand,³ R. Venick,⁴ E. Alonso,⁵ J. Mitchell,³ R. Annunziato,¹ G. Mazariegos,⁶ B. Shneider.⁷
The mTORC2 Activation Is Critical for Hepato-Cytoprotection Against Ischemia and Reperfusion Injury.

H. Zhou,^1,2 J. Zhu,^1,3 S. Yue,¹ R. Busuttil,¹ J. Kupiec-Weglinski,¹ X. Wang,² Y. Zhai.¹
The Oldest and Coldest in Kidney Paired Donation: Experience of the National Kidney Registry.

N. Nassiri,¹ L. Kwan,¹ J. Sinacore,² J. Veale.¹
The Optimal Time Point for Steroid Withdrawal After Kidney Transplantation Is One Year After Engraftment.

M. Haller,¹ M. Kammer,^1,2 A. Kainz,² G. Heinze,¹ R. Oberbauer.^1,2
The Phenotypic Diversity of Late Silent Antibody-Mediated Rejection.

F. Eskandary,^1,2 J. Reeve,^1,3 H. Regele,⁴ L. Hidalgo,^1,3 D. Yoo,¹ N. Kozakowski,⁴ K. Famulski,¹ G. Böhmig,² P. Halloran.^1,5
The Prediction of Molecular ABMR by Anti-HLA Donor-Specific Antibody Properties.

F. Eskandary,^1,2 J. Reeve,^1,3 D. Yoo,¹ H. Regele,⁴ L. Hidalgo,^1,3 G. Böhmig,² P. Halloran.^1,5
The Presence of CMV-Specific T-Cells in CMV-Seronegative Kidney Transplant Recipients Predicts Outcome After Kidney Transplantation.

T. Schachtner,^1,2 M. Stein,² P. Reinke.^1,2
The Prevailing Preference for Left Nephrectomy in Living Donor Transplantation Does Not Adversely Affect Long Term Donor Outcome.

S. Robertson,¹ L. Garrard,¹ S. Farid,¹ R. Baker,¹ N. Ahmad,¹ M. Attia,¹ R. Feltbower,² M. Jameel,¹ H. Lutz.¹
The Preventive and Therapeutic Effect of Immunoglobulin on Infectious Complications in Donation After Cardiac Death Liver Transplant Recipients: A Prospective Randomized Controlled Study.

A. Yang, Z. Guo, W. Ju, Y. Chen, M. Han, X. Wang, D. Wang, Y. Ma, A. Hu, X. Zhu, X. He.
The Property of Modulatory T Cells Generated by Mixed Lymphocyte Culture with CD154 Blockade.

K. Hotta, T. Oura, B. Cosimi, T. Kawai.
The Quilty Effect in Pediatric Heart Transplant Recipients.

A. Joong,¹ M. Richmond,¹ K. Stack,² R. Rodriguez,¹ J. McAllister,² W. Zuckerman,¹ T. Lee,¹ S. Law,¹ L. Addonizio.¹
The Relationship Between Kidney Donor Profile Index and Six Month eGFR in Deceased Donor Recipients.

D. Keith, A. Nishio Lucar, G. Vranic.
The Role and Mechanism of CD40/CD40L Expression on Different T-Cell Subsets.

N. Granofszky, K. Hock, B. Mahr, N. Pilat-Michalek, T. Wekerle.
The Role of B Cells in Liver Transplant Tolerance.

M. Morita,² G. Enyindah-Asonye,¹ N. Gupta,¹ J. Fung,² S. Qian,^1,2 L. Lu.^1,2
The Role of HLA Class II Antibody in Endothelial Cell Activation and Allograft Rejection.

G. Cantanhede,¹ V. Carter,² K. Giles,² J. Kirby,¹ S. Ali.¹
The Role of Obesity in Survival Outcomes of Liver Transplant Recipients with High MELD Score.

S.-H. Chang,¹ N. Carlsson,¹ X. Liu,² J. Wellen,³ J. Hagopian,⁴ T. Horwedel,⁴ T. Alhamad.⁵
The Role of Palliative Care in the Thoracic Transplant Multidisciplinary Care Team: Barriers and Benefits.

A. Manfredi,¹ C. Toevs.²
The Role of PI3kγ and PI3kδ in Alloimmunity.

M. Uehara,¹ A. Jamil,¹ Z. Solhjou,¹ M. McGrath,¹ N. Banouni,¹ C. Evans,² J. Dinitto,² D. Winkler,² R. Abdi.¹
The Role of Short-Term Ventricular Assist Device in Patients with Cardiogenic Shock – Is It Really a Solution?

A. Popov, M. Zeriouh, S. Anton, W. Alexander, Z. Bartlomiej, D. Garcia, P. Mohite, A. Padukone, A. Koch, O. Ananiadou, L. Fazekas, A. Simon.
The Safety and Efficacy of Suspended Gasless Laparoscopy Living-Donor Nephrectomy in Renal Transplantation.

J. Tian.
The Significance of Microvascular Inflammation in Antibody-Mediated Rejection in ABO-Incompatible Kidney Transplantation.

H. Ishihara,¹ H. Ishida,¹ K. Unagami,² T. Hirai,¹ M. Okumi,¹ K. Omoto,¹ T. Shimizu,¹ K. Tanabe.¹
The Simplified EPTS Score: Who Wins and Who Loses?

J. Schold, E. Poggio, R. Fatica, S. Flechner, L. Buccini, D. Goldfarb.
The Surgical Preconditioning in Patients with Ultra-Short Gut Using a Native Colonic Conduit for Anticipated Visceral Transplantation.

M. Fujiki, K. Hashimoto, A. Khanna, K. Abu-Elmagd.
The Survival Benefit of Pancreas and/or Kidney Transplantation for Patients with Type 1 Diabetes.

R. Gruessner, V. Whittaker, N. Ozden, A. Gruessner.
The Therapeutic Potential of Human Liver-Derived Stem Cell Transplantation in a Cirrhotic Liver Rat Model.

S. Lee,¹ J.-H. Lee,² H.-J. Park,² Y.-A. Kim,² M.-N. Park,² S.-K. Lee.¹
The Treatment of Borderline Lesion in Protocol Biopsies Did Not Improve the Outcome in Kidney Transplant Recipients.

A. Flores-Mendoza, L. Marino-Vazquez, A. Guichard-Romero, N. Uribe-Uribe, R. Rivera-Marfil, A. Nuñez-Abreu, J. Alberu, L. Morales-Buenrostro.
The UK Kidney Donor Risk Index Score Predicts the Development of TRAS Post Deceased Donor Transplantation.

M. Willicombe, A. Baheerathan, S. Moser, A. McLean, M. Hammady, W. Gedroyc, D. Taube.
The UK ONE Study: Safety and Feasibility of Regulatory T Cell Therapy in Renal Transplantation.

A. Bushell,¹ J. van der Net,^1,2 D. Game,³ R. Hilton,³ S. Thirkell,⁴ P. Friend,² E. Geissler,⁵ K. Wood,¹ P. Harden,² G. Lombardi.⁴
The UKKDRI Score Predicts Outcomes of Deceased Donor Transplantation Using a Steroid Sparing Immunosuppressive Protocol.

A. Wardle, M. Willicombe, D. Goodall, A. McLean, D. Taube.
The Urine Common Rejection Module (uCRM) Is a Sentinal Assay for Graft Rejection.

T. Sigdel,¹ T. Tran,¹ O. Bestard,² F. Vincenti,¹ M. Sarwal.¹
The Use of Kidney Donors Older Than 80 Years Does Not Affect Graft Survival in the Medium Term.

A. Fernández,¹ J. González,² C. Galeano,¹ S. Elias,¹ S. Jimenez,¹ F. Caravaca,¹ S. Pampa,¹ R. Marcen.¹
The Use of Kidneys with Acute Kidney Injury: The Good, the Bad and the Ugly.

C. Boffa,^1,2 F. van de Leemkolk,¹ E. Curnow,³ J. Gilbert,² E. Sharples,^1,2 R. Ploeg.^1,2
The Use of Perioperative Lactate Values as Markers for Adverse Outcomes in Liver Transplantation.

B. Rao,¹ A. Yoshida,³ M. Ibrahim,² S.-M. Jafri.²
The Use of Sofosbuvir (SOF)-Containing Direct Antiviral Agents (DAA)-Based Regimens Requires Increase in Tacrolimus (Tac) Doses in Kidney Transplant (KT) Recipients with Hepatitis C Virus (HCV) Infection.

N. Polanco Fernandez,¹ A. García Santiago,¹ M. Fernández Ruiz,² R. Muñoz,³ C. Alvarez Vazquez,⁴ A. Hernandez,¹ V. Mercado,¹ E. González Monte,¹ I. Fernández,³ J. Aguado,² M. Praga,¹ A. Andres.¹
The Use of Thromboelastography (TEG) in Preoperative Pediatric Liver Transplantation to Predict Postoperative Thrombotic Complications.

K. Curiel,¹ B. Wicklund,² K. Gonzalez,¹ W. Andrews,¹ V. Fioravanti,¹ R. Hendrickson.¹
The In Vivo Non-Invasive Long-Term Functional Assessment of Neuronal Regeneration in Vascularized Composite Allotransplantation.

C.-J. Wen,^1,2 C.-H. Lin,¹ S.-L. Peng,^3,4 F.-N. Wang,³ L.-Y. Huang,³ H.-Y. Cheng,¹ H.-H. Hsu,¹ X.-T. Huang,¹ C.-H. Lin,¹ F.-C. Wei.¹
Therapeutically Equivalent Results to Caucasians in Black Kidney Transplant Recipients Using ASTAGRAF XL^® Despite a Higher Degree of HLA Mismatch : A Post-Hoc Analysis of Phase III Data from Over 2000 Patients.

J. Schwartz, S. Wilson, F. Shi, N. Undre, M. Kumar.
Thoracic Simulated Allocation Modeling (TSAM) of Broader Sharing.

M. Colvin,¹ M. Skeans,¹ L. Robbins Callahan,² L. Edwards,² J. Zeglin,¹ S. Silvestry,³ R. Davies,⁴ M. Farr,⁵ A. Israni,¹ J. Rogers.⁶
Thoracic Simulation Allocation Modeling (TSAM) of a 6-Tier Allocation Strategy.

M. Colvin,¹ M. Skeans,¹ L. Robbins Callahan,² L. Edwards,² J. Zeglin,¹ S. Silvestry,³ R. Davies,⁴ M. Farr,⁵ A. Israni,¹ J. Rogers.⁶
Thorough Pre-Transplant Evaluation and Appropriate Case Selection Is the Mainstay for Better Survival in Recipients with Malignancy.

W. Yin.^1,2
Three Months of Weekly Rifapentine Plus Isoniazid for Latent Tuberculosis Treatment in Solid Organ Transplant Candidates.

B. Knoll,¹ R. Nog,¹ Y. Wu,² A. Dhand.¹
Three-Year Graft Loss Risk in Kidney Transplants: Dynamic Patient Level Data Improve Predictive Efficacy.

T. Srinivas, J. Zhang, Z. Su, D. Taber, J. Marsden, K. Reilly, D. Northrup, J. Long, L. Lenert, W. Moran, P. Mauldin.
Three-Year Outcome After HSCT with Subsequent KT from the Same Haploidentical Donor without Immunosuppression.

C. Schwarz,¹ A. Lawitschka,² G. Böhmig,³ E. Dauber,⁴ H. Greinix,⁵ N. Kozakowski,⁶ F. Mühlbacher,¹ G. Berlakovich,¹ T. Wekerle.⁷
Thrombalexin: Detection & Efficacy of a Membrane-Bound Anti-Thrombin Agent.

M. Manook,^1,2 J. Kwun,¹ J. Yoon,¹ S. Sacks,² A. Dorling,² N. Mamode,² R. Smith,² S. Knechtle.¹
Thrombolytic Protocol in Organ Procurement from Donation After Circulatory Death Donors Reduces Ischemic Cholangiopathy in Liver Transplantation.

J. Fan, G. Selvaggi, W. De Faria, S. Nishida, A. Tekin, T. Beduschi, Y. Yushkov, R. Vianna.
Thrombotic Microangiopathy After Kidney Transplantation: A Rare but Serious Complication.

C. Teixeira, I. Pietrobom, A. Lima, N. Tenório, G. Basso, M. Cristelli, L. Viana, G. Kirsztajn, H. Tedesco-Silva, J. Medina-Pestana.
Thymus Is Required for T Cells Reconstitution Following Antibody-Mediated Lymphoablation.

K. Ayasoufi, R. Fan, A. Valujskikh.
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.

S. Helmke,¹ J. O'Leary,² J. Burton,¹ M. Cookson,¹ S. Lauriski,¹ J. Trotter,² J. McHutchison,³ G. Everson.¹
Time for the Grown Ups to Split the Difference? Outcomes of Two Adult Split Liver Transplants in the USA.

K. Halazun, E. Przybyszewski, B. Samstein, E. Verna, A. Fox, J. Guarrera, T. Kato, A. Griesemer, R. Brown, J. Emond.
Time Trends of Induction Agent Use in Older and Younger Kidney Transplantation Recipients.

Q. Huang, X. Luo, M. McAdams-DeMarco, D. Segev.
Tipping the Scales: Liver Transplant Outcomes of the Super Obese.

R. Gedaly, J. Berger, X. Mei, F. Marti, L. Turcios, M. Shah.
Tissue Inhibitor of Metalloproteinase-3 (TIMP-3) Protects Against Loss of Hepatic Integrity After Ischemia-Reperfusion Injury.

T. Fujii, S. Duarte, R. Busuttil, A. Coito.
Tissue Priming of Plasmacytoid Dendritic Cells Enhances Their Phagocytosis and Lowers the Threshold for Subsequent Toll-Like Receptor 7/9 Activation.

J. Ruben,¹ G. Garcia-Romo,¹ E. Breman,¹ S. van der Kooij,¹ A. Redeker,² R. Arens,² C. van Kooten.¹
TNT009 and Its Parental Mouse Monoclonal Antibody TNT003 Target Complement Component C1s and Effectively Block Alloantibody-Induced Classical Complement Pathway Activation – The Preclinical Experience.

M. Wahrmann,¹ J. Mühlbacher,¹ H. Regele,¹ F. Eskandary,¹ J. Gilbert,² S. Panicker,² G. Böhmig.¹
Tocilizumab as Treatment for Persistent Chronic Active Antibody Mediated Rejection.

H. Fernandez, S. Patel, M. Chiles, L. Ratner, R. Crew.
Tofacitinib Delivered by Solid Lipid Nanoparticles Inhibits Dendritic Cell Maturation and Their Allostimulatory Capacity.

J. Budihardjo,¹ M. Iglesias,¹ J. Walch,¹ X. Calderon-Colon,² W. Lee,¹ G. Brandacher,¹ J. Patrone,² G. Raimondi.¹
Tolerance Induction in Vascularized Composite Allotransplantation with Peri-Transplant Combined Costimulation Blockade.

B. Oh,¹ G. Furtmüller,¹ M. Fryer,¹ J. Grahammer,² S. Schneeberger,² D. Cooney,¹ G. Raimondi,¹ G. Brandacher.¹
Tolerance Induction with Donor Bone Marrow Transplantation in Kidney Transplantation.

H. Park,¹ N. Lee,¹ S. Lee,¹ G. Choi,¹ C. Kwon,¹ S. Kim,¹ J.-W. Joh,¹ M. Kim,² Y. Kwon,² S.-K. Lee.¹
Tolerogenic Interactions Between Host CD8⁺Myeloid Dendritic Cells and Natural Killer T Cells Are Required for Acceptance of Combined Organ and Bone Marrow Transplants After TLI Conditioning.

D. Hongo Apum,¹ X. Zhang,² E. Engleman,² S. Strober.¹
Toll-Like Receptor (TLR) 9-Induced Resistance to Murine Cardiac Allograft Tolerance Is Dependent Upon C3a and C5a Receptor (C3aR/C5aR) Signaling.

J. Sheen, P. Heeger.
Tool to Assess Risk of Non-Adherence in Renal Transplant Candidates.

T. Kaiser,¹ K. Daley,² L. Dick,² L. Deye,² N. Parrish,² J. Huff,² A. Govil,¹ B. Abu Jawdeh,¹ G. Mogilishetty,¹ R. Alloway,¹ E. Woodle.¹
Torque Teno Virus – Inverse Association with Late Silent Antibody Mediated Kidney Allograft Rejection.

G. Bond,¹ M. Schiemann,¹ F. Eskandary,¹ H. Herkner,² E. Puchhammer,³ R. Oberbauer,¹ G. Böhmig.¹
Total Pancreatectomy with Islet Autotransplantation for Chronic Pancreatitis: Considerations for Early Intervention.

J. Jolissaint,¹ L. Langman,¹ C. DeBolt,¹ A. Wang,² D. Strand,² V. Zaydfudim,¹ R. Adams,¹ K. Brayman.¹
Tracking Endogenous B Cells Recognizing Allogeneic MHC Class II in Mice.

J. Yang,^1,2 J. Chen,¹ A. Akl,¹ R. Sciammas,³ A. Chong.¹
Tracking of Endogenous Graft-Reactive Tregs Reveals Their Peripheral Enrichment During Transplantation Tolerance.

J. Young,¹ J. Chen,¹ M. Miller,¹ D. Yin,¹ J. Moon,² M.-L. Alegre,¹ A. Chong.¹
Traditionally Unacceptable Organs Promote Liver Transplantation in Patients with Long Waiting Times in the Share 35 Era.

E. Siskind,¹ T. MacDonald,² R. Barth,¹ J. LaMattina,¹ D. Bruno,¹ S. Hanish.¹
Transcatheter Aortic Valve Replacement (TAVR) for Severe Aortic Stenosis as a Bridge to Liver Transplantation.

R. Syed, P. Cox-Alomar, H. Bohorquez, G. Therapondos, N. Girgrah, S. Joshi, G. Tyson, T. Reichman, I. Carmody, G. Loss, A. Cohen, D. Bruce, E. Ahmed, J. Seal, P. Parrino, S. Ramee, N. Bzowej.
Transcriptome Profiles in Peripheral Blood of Kidney Graft Recipients.

J.-W. Seo,¹ H. Moon,¹ Y.-G. Kim,¹ K.-H. Jeong,¹ S.-J. Ihm,² J.-Y. Moon,¹ S.-H. Lee.¹
Transfer of Donor-Derived Exosomes to Recipient Ag-Presenting Cells Is Critical for Allograft Recognition.

Q. Liu,¹ D. Rojas-Canales,¹ S. Divito,¹ W. Shufesky,¹ A. Larregina,² A. Morelli.¹
TRANSFORM: A Modern Approach to Evaluate Long-Term Outcomes of Everolimus with Reduced-Calcineurin Inhibitors in De Novo Kidney Transplant Recipients[mdash]Baseline Characteristics.

M. Henry.
Transient Hepatitis B Core Positivity After Administration of IVIG for Desensitization (DES).

A. Nejad, A. Vo, J. Choi, S. Jordan.
Transitional B Cell T1/T2 Ratio Is a Prognostic Marker for Human Renal Allograft Deterioration.

A. Cherukuri,¹ D. Rothstein,¹ R. Baker.²
Transplant Education Increases Wait-Listing Rates in Dialysis Centers with Supportive Administration and Knowledgeable Staff.

A. Waterman,¹ J. Peipert,¹ H. Xiao,² C. Goalby,¹ K. Lentine.²
Transplant Specialized Community Pharmacists' Role in Care Transitions for Transplant Patients.

D. Nguyen,^1,2 N. Rickles,² C. Rogers,³ K. Richards,³ J. Thomas,¹ A. Loring,¹ H. Kirkham,¹ M. Kang,¹ K. Poliskey.¹
Transplantation for Hepatocellularcarcinoma Is There a Tumor Size Limit?

A. Daoud, L. Teeter, M. Ghobrial, E. Graviss, S. Mogawer, A. Sholkamy, M. Alshazly, H. Monsour, A. Gaber.
Transplantation of Islet Preconditioned with Hydrogen Sulfide Enhances the Graft Function in Diabetic Mice.

D. Wang, M. Ding, J. Xue, J. Zheng, S. Feng, H. Tian, Y. Li.
Transplanting the Extremely Sensitized Patient: The University of Wisconsin Experience with the New Kidney Allocation System.

E. Grodstein, R. Bennett, J. Anderson, G. Press, A. Djamali, D. Kaufman, R. Redfield.
Transplants without Borders – A Project for In Locus Training of New Transplants Centers in Brazil.

M. Perosa,¹ J. Branez,¹ L. Mota,¹ B. Zeballos,¹ H. Noujaim,¹ L. Ianhez,¹ L. Alvim,¹ D. Machado,¹ M. Moreno,¹ T. Genzini,¹ R. Kandaswamy.²
Treatment for AMR and DSA: A Center Based Review of Pediatric Orthotopic Heart Transplant Recipients.

D. Drogalis-Kim,¹ M. Hickey,² J. Alejos,¹ E. Reed,² N. Halnon.¹
Treatment of Hepatitis C Viral Infection with Novel Direct Acting Antivirals in Kidney Transplant Recipients – Single Center Experience.

K. Hatahet,¹ M. Ghanta,¹ A. Gillespie,¹ I. Lee,¹ H. El-Halawany,² K. Qureshi,² K. Lau,³ S. Karhadkar,³ A. Di Carlo,³ S. Constantinescu,¹ S. Rao.¹
Treatment of Late Antibody-Mediated Rejection: Observations from Clinical Practice.

G. Einecke,¹ J. Bräsen,² A. Schwarz,¹ H. Haller,¹ F. Njau.¹
Treatment of Post-Transplant Focal Glomerulosclerosis: The Effect on Histopathology Lesions and Podocyte Foot Process Effacement.

K. Koutroutsos,¹ J. Moss,² L. Moran,² T. Cook,² R. Charif,¹ D. Taube,¹ C. Roufosse,² M. Loucaidou.¹
Treatments Against Renin-Angiotensin-Aldosterone System Could Influence FGF23 and Klotho Levels in Renal Transplant Recipients.

S. Sezer,¹ E. Tutal,¹ Z. Bal,¹ M. Uyar,¹ M. Haberal.²
Treg-Rich Organized Lymphoid Structures (TOLS) in Spontaneously Accepted Mouse Kidney Allografts.

C. Yang,¹ E. Farkash,² D. Ndishabandi,¹ R. White,¹ B. Jiang,¹ I. Aljabban,¹ P. Russell,¹ J. Madsen,¹ R. Colvin,¹ A. Alessandrini.¹
Trends in Aspergillus Infection After Liver Transplantation, 1988-2014.

R. Al Masri, L. Jennings, S. Asrani, G. Klintmalm, C. Spak.
Trends in Liver Transplant Rates and Waitlist Survival.

M. Bowring, A. Massie, X. Luo, L. Kucirka, E. Chow, A. Cameron, D. Segev.
Tumor-Necrosis-Factor-α Antagonist Therapy for Inflammatory Bowel Disease After Liver Transplantation.

R. Parekh, M. Segovia, N. Kaur.
Twenty Years of Evolving Trends in Racial Disparities for Adult Kidney Transplant Recipients.

D. Taber, M. Gebregziabher, K. Chavin, T. Srinivas, P. Baliga, L. Egede.
Two-Year Safety Results from the Phase 3b Switching Study of Kidney Transplant Patients with Tremor to LCP-Tacro (STRATO) Study.

S. Steinberg,¹ R. Gedaly,² L. Chan,³ A. Langone.⁴
Type of Sensitization Does Not Impact Kidney Graft Outcome in Weakly Sensitized Patients.

A. Morrison,¹ D. Sawinski,² M. Lim,² M. Levine,¹ M. Kamoun,³ P. Porrett.¹
Type-I Interferon Induced Cross-Competition of IL-10 Signaling and Its Role in the Abrogation of Transplant Tolerance.

M. Iglesias, A. Arun, W. Lee, G. Brandacher, G. Raimondi.